Author:
Eger William H.,Mutchler Alexa,Santamour Tim,Meaders Shelby,Pines Heather A.,Bazzi Angela R.,Tookes Hansel E.,Bartholomew Tyler S.
Abstract
Abstract
Introduction
People who use drugs (PWUD) are at increased risk for HIV infection. HIV self-testing (HIVST) is a promising method for identifying new infections, but optimal distribution strategies remain understudied.
Methods
To characterize PWUD by HIVST distribution strategy (peers vs. mail), we examined data from July 2022 to June 2023 collected from a real-world HIVST program led by the non-profit, Florida Harm Reduction Collective. We used descriptive statistics and Poisson regressions with robust error variance to compare those who received HIVST through peers or via mail by socio-demographics, Ending the HIV Epidemic (EHE) county designation, and HIV testing experience.
Results
Among 728 participants, 78% received HIVST from peers, 47% identified as cisgender female, 48% as heterosexual, and 45% as non-White; 66% resided in an EHE county, and 55% had no HIV testing experience. Compared to those who received an HIV self-test from peers, those who received tests via mail were less likely to be cisgender male (vs. cisgender female; prevalence ratio [PR] = 0.59, 95% confidence interval [CI]: 0.43, 0.81), non-Hispanic Black (vs. non-Hispanic White; PR = 0.57, 95% CI: 0.36, 0.89) or from EHE counties (vs. non-EHE counties; PR = 0.33, 95% CI: 0.25, 0.44). Those who received tests via mail were also more likely to identify their sexual orientation as “Other/Undisclosed” (vs. straight/heterosexual; PR = 2.00, 95% CI: 1.51, 2.66).
Conclusion
Our findings support the role of community-based HIVST distribution strategies in increasing HIV testing coverage among PWUD. Additional research could help inform the equitable reach of HIVST.
Funder
Centers for Disease Control and Prevention Foundation
National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Vorobjov S, Uusküla A, Des Jarlais DC, Abel-Ollo K, Talu A, Rüütel K. Multiple routes of drug administration and HIV risk among injecting drug users. J Subst Abuse Treat. 2012;42(4):413–20.
2. Centers for Disease Control and Prevention. HIV and Injection Drug Use. In: Division of HIV/AIDS Prevention, editor. 2021.
3. Edeza A, Bazzi A, Salhaney P, Biancarelli D, Childs E, Mimiaga MJ, et al. HIV Pre-exposure Prophylaxis for people who inject drugs: the context of co-occurring injection- and sexual-related HIV risk in the U.S. Northeast. Subst Use Misuse. 2020;55(4):525–33.
4. Linley L, Johnson AS, Song R, Hu S, Wu B, Hall HI et al. Estimated HIV incidence and prevalence in the United States 2010–2019. 2021.
5. Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD, et al. Opioid use fueling HIV Transmission in an urban setting: an outbreak of HIV infection among people who inject Drugs-Massachusetts, 2015–2018. Am J Public Health. 2020;110(1):37–44.